Filtered By:
Specialty: Cardiology
Cancer: Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 24 results found since Jan 2013.
TRIM65 Suppresses oxLDL-induced Endothelial Inflammation by Interaction with VCAM-1 in Atherogenesis
CONCLUSION: Our studies indicate that TRIM65 attenuates the endothelial inflammatory response by targeting VCAM-1 for ubiquitination and provides a potential therapeutic target for the inhibition of endothelial inflammation in AS.PMID:37608612 | DOI:10.2174/0929867331666230822152350
Source: Atherosclerosis - August 23, 2023 Category: Cardiology Authors: Xiao-Feng Ma Yi-Ren Zhou Zhi-Xiang Zhou Hui-Ting Liu Bo-Bin Zhoua Nian-Hua Deng Kun Zhou Zhen Tian Ze-Fan Wu Xi-Yan Liu Ming-Gui Fu Zhi-Sheng Jiang Source Type: research
PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology
Cancers (Basel). 2023 Feb 22;15(5):1397. doi: 10.3390/cancers15051397.ABSTRACTCancer patients treated with immune checkpoint inhibitors (ICIs) are exposed to a high risk of atherosclerosis and cardiometabolic diseases due to systemic inflammatory conditions and immune-related atheroma destabilization. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key protein involved in metabolism of low-density lipoprotein (LDL) cholesterol. PCSK9 blocking agents are clinically available and involve monoclonal antibodies, and SiRNA reduces LDL levels in high-risk patients and atherosclerotic cardiovascular disease events in m...
Source: Atherosclerosis - March 11, 2023 Category: Cardiology Authors: Vincenzo Quagliariello Irma Bisceglia Massimiliano Berretta Martina Iovine Maria Laura Canale Carlo Maurea Vienna Giordano Andrea Paccone Alessandro Inno Nicola Maurea Source Type: research
Pharmacological Inhibition of P-Rex1/Rac1 Axis Blocked Angiotensin II-Induced Cardiac Fibrosis
ConclusionOur findings demonstrated for the first time that P-Rex1 was an essential signaling mediator in CFs activation and subsequent cardiac fibrosis, and 1A-116 could be a potential pharmacological development drug.
Source: Cardiovascular Drugs and Therapy - March 9, 2023 Category: Cardiology Source Type: research
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond
Curr Atheroscler Rep. 2022 Jul 29. doi: 10.1007/s11883-022-01057-z. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: Since the discovery of PCSK9 in 2003, this proprotein convertase was shown to target specific receptors for degradation in endosomes/lysosomes, including LDLR and other family members and hence to enhance the levels of circulating LDL-cholesterol (LDLc). Accordingly, inhibitors of PCSK9, including monoclonal antibodies blocking its circulating activity and siRNA silencers of its hepatic expression, are now used in clinics worldwide to treat hypercholesterolemia patients effectively and safely in combination ...
Source: Atherosclerosis - July 29, 2022 Category: Cardiology Authors: Nabil G Seidah Damien Gar çon Source Type: research
Oridonin attenuates low shear stress-induced endothelial cell dysfunction and oxidative stress by activating the nuclear factor erythroid 2-related factor 2 pathway
CONCLUSIONS: In conclusion, the results of the present study suggested that oridonin may ameliorate LSS-induced EC dysfunction and oxidative stress by activating NRF2, thereby attenuating AS.PMID:35799227 | DOI:10.1186/s12906-022-03658-2
Source: Atherosclerosis - July 7, 2022 Category: Cardiology Authors: Zhipeng Chen Heqian Liu Xiaoqi Zhao Subinur Mamateli Cheng Liu Lei Wang Jing Yu Yutong Liu Jing Cai Tong Qiao Source Type: research
Capmatinib suppresses LPS-induced interaction between HUVECs and THP-1 monocytes through suppression of inflammatory responses
CONCLUSION: These findings imply that CAP improves inflamed endothelial-monocyte adhesion via a PPAR/IL-10-dependent pathway. The current study provides in vitro evidence for a therapeutic approach for treating atherosclerosis.PMID:35483573 | DOI:10.1016/j.bj.2022.04.005
Source: Atherosclerosis - April 28, 2022 Category: Cardiology Authors: Hyung Sub Park A M Abd El-Aty Ji Hoon Jeong Taeseung Lee Tae Woo Jung Source Type: research
Possible causes of atherosclerosis: lncRNA < em > COLCA1 < /em > induces oxidative stress in human coronary artery endothelial cells and impairs wound healing
CONCLUSIONS: OxLDL can up-regulate the expression of COLCA1 in HCAECs, which in turn affects the intracellular COLCA1/hsa-miR-371a-5p/SPP1 pathway to regulate the level of oxidative stress in cells. This in turn affects the level of apoptosis and wound healing ability, which causes cells to produce a continuous inflammatory response.PMID:35434044 | PMC:PMC9011302 | DOI:10.21037/atm-22-507
Source: Atherosclerosis - April 18, 2022 Category: Cardiology Authors: Ming-Peng Li Zi-Chen Hao Meng-Qi Yan Chun-Li Xia Zhong-Hua Wang Ying-Qing Feng Source Type: research
Indoleamine 2,3-Dioxygenase 1 (IDO1) Promotes Cardiac Hypertrophy via a PI3K-AKT-mTOR-Dependent Mechanism
Cardiovasc Toxicol. 2021 May 21. doi: 10.1007/s12012-021-09657-y. Online ahead of print.ABSTRACTIndoleamine 2,3-dioxygenase 1 (IDO1) is an enzyme for tryptophan metabolism, involved in immune cell differentiation/maturation and cancer biology. IDO1 is also expressed in cardiomyocytes, but its roles in the cardiovascular system are not fully understood. Here, we reported the functions of IDO1 during cardiac hypertrophy. Quantitative real-time PCR and Western blot experiments demonstrated the upregulation of IDO1 mRNA and protein levels in human and hypertrophic mouse hearts, as well as in angiotensin II (Ang II)-induced hyp...
Source: Cardiovascular Toxicology - May 22, 2021 Category: Cardiology Authors: Yang Liu Shuang Li Zhanqun Gao Shuangjia Li Qingyun Tan Yanmei Li Dongwei Wang Qingdong Wang Source Type: research
